Zytiga (Prostate Cancer) - Forecast and Market Analysis to 2022


#163790

48pages

GlobalData

$ 6995

In Stock

Zytiga (Prostate Cancer) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Zytiga (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

J&J’s Zytiga is an orally-bioavailable small molecule that the body converts to abiraterone, an androgen biosynthesis inhibitor. Abiraterone inhibits the enzyme CYP17 which interferes with androgen biosynthesis. In contrast to other hormone therapies, Zytiga interferes with testosterone production, not just in the testes but also in the adrenal glands and the tumor itself (Zytiga Prescribing Information, 2011). The Zytiga indication for mCRPC also differentiates it from the products used in ADT.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Zytiga including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Zytiga for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Zytiga performance 
  • Obtain sales forecast for Zytiga from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 9

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 11
3.1.4 Quality of Life 12
3.2 Symptoms 12

4 Disease Management 13
4.1 Diagnosis and Referral Overview 13
4.2 Treatment Overview 15
4.2.1 Conservative Management Strategies 19
4.2.2 Localized Treatments 20
4.2.3 Hormone Therapy 21
4.2.4 Drug Therapies 23

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Zytiga (abiraterone acetate) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 31
6.4 SWOT Analysis 31
6.5 Forecast 33

7 Appendix 35
7.1 Bibliography 35
7.2 Abbreviations 39
7.3 Methodology 41
7.4 Forecasting Methodology 41
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 41
7.4.2 Percent Drug-treated Patients 42
7.4.3 Percent Hormone Therapy-Treated Patients 42
7.4.4 General Pricing Assumptions 42
7.4.5 Individual Drug Assumptions 44
7.4.6 Generic Erosion 45
7.5 Physicians and Specialists Included in This Study 45
7.6 Survey of Prescribing Physicians 46
7.7 About the Authors 47
7.7.1 Authors 47
7.7.2 Global Head of Healthcare 47
7.8 About GlobalData 48
7.9 Contact Us 48
7.10 Disclaimer 48

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 11
Table 2: Global Variations in Recommendations on Routine PSA Screening 13
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 16
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 18
Table 5: Leading Treatments for Prostate Cancer, 2012 28
Table 6: Product Profile - Zytiga 30
Table 7: Zytiga SWOT Analysis, 2012 32
Table 8: Global Sales Forecasts ($) for Zytiga, 2012-2022 34
Table 9: Physicians Surveyed, By Country 46

Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 17